Cohance Lifesciences Ltd vs Solara Active Pharma Sciences Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 05, 2026

Key Highlights

The Latest Trading Price of Cohance Lifesciences Ltd is ₹ 454.6 as of 05 May 15:30 . The P/E Ratio of Cohance Lifesciences Ltd changed from 34.8 on March 2021 to 110.3 on March 2025 . This represents a CAGR of 25.95% over 5 yearsThe P/E Ratio of Solara Active Pharma Sciences Ltd changed from 22.6 on March 2021 to 3943 on March 2025 . This represents a CAGR of 180.78% over 5 years The Market Cap of Cohance Lifesciences Ltd changed from ₹ 12611 crore on March 2021 to ₹ 29524 crore on March 2025 . This represents a CAGR of 18.55% over 5 yearsThe Market Cap of Solara Active Pharma Sciences Ltd changed from ₹ 5009 crore on March 2021 to ₹ 2005 crore on March 2025 . This represents a CAGR of -16.73% over 5 years The revenue of Cohance Lifesciences Ltd for the Dec '25 is ₹ 550.71 crore as compare to the Sep '25 revenue of ₹ 571.17 crore. This represent the decline of -3.58% The revenue of Solara Active Pharma Sciences Ltd for the Dec '25 is ₹ 349 crore as compare to the Sep '25 revenue of ₹ 314.03 crore. This represent the growth of 11.14% The ebitda of Cohance Lifesciences Ltd for the Dec '25 is ₹ 96.65 crore as compare to the Sep '25 ebitda of ₹ 136.55 crore. This represent the decline of -29.22% The ebitda of Solara Active Pharma Sciences Ltd for the Dec '25 is ₹ 30.59 crore as compare to the Sep '25 ebitda of ₹ 35.22 crore. This represent the decline of -13.15% The net profit of Cohance Lifesciences Ltd changed from ₹ 75.37 crore to ₹ 29.02 crore over 7 quarters. This represents a CAGR of -42.04% The net profit of Solara Active Pharma Sciences Ltd changed from ₹ -13.46 crore to ₹ -17.43 crore over 7 quarters. This represents a CAGR of 15.92% The Dividend Payout of Cohance Lifesciences Ltd changed from 16.5 % on March 2021 to 0 % on March 2025 . This represents a CAGR of -100.00% over 5 yearsThe Dividend Payout of Solara Active Pharma Sciences Ltd changed from 11.38 % on March 2021 to 0 % on March 2025 . This represents a CAGR of -100.00% over 5 years .

About Cohance Lifesciences Ltd

Cohance Lifesciences Limited, formerly known as Suven Pharmaceuticals Limited was incorporated on November 6, 2018.
The name of the Company has been changed to Cohance Lifesciences Limited w.e.f.
May 7, 2025.
Cohance Lifesciences Ltd is an integrated Contract Development and Manufacturing Operations (CDMO) company that serves leading global life science and fine chemical majors.
The Company's comprehensive services encompass- Custom Synthesis, Process R&D, Scale-Up, and Contract Manufacturing of intermediates, APIs, and formulations. Company is engaged in the business of development and manufacturing of New Chemical Entity (NCE) based Intermediates, Active Pharmaceutical Ingredients (API), Speciality Chemicals and formulated drugs under contract research and manufacturing services for global pharmaceutical, biotechnology and chemical companies.

About Solara Active Pharma Sciences Ltd

Solara Active Pharma Sciences Limited was incorporated on February 23, 2017 to undertake business in manufacturing, production, processing, formulating, sale, import, export, merchandising, distributing, trading of and dealing in active pharmaceutical ingredients (APIs).
The Company has 6 APIs manufacturing plants located in Ambernath, Mangalore, Mysuru, Puducherry, Vishakhapatnam, and Cuddalore with a capacity of over 2,580 kilo litres and two R&D Centres in Chennai and Bengaluru. The Company offer rich basket of niche high-value products for global markets.
The Company has developed 80+ commercial APIs predominantly in anthelmintic, anti-malarias, anti-infective, neuromuscular insomnia and anti-psychotic hyperkalemia segments, among others.
These drugs primarily deal with anthelmintic, anti-malarias, beta blockers, muscle relaxants, novel oral anticoagulants, anti-infective and other niche segments.

FAQs for the comparison of Cohance Lifesciences Ltd and Solara Active Pharma Sciences Ltd

Which company has a larger market capitalization, Cohance Lifesciences Ltd or Solara Active Pharma Sciences Ltd?

Market cap of Cohance Lifesciences Ltd is 17,978 Cr while Market cap of Solara Active Pharma Sciences Ltd is 1,875 Cr

What are the key factors driving the stock performance of Cohance Lifesciences Ltd and Solara Active Pharma Sciences Ltd?

The stock performance of Cohance Lifesciences Ltd and Solara Active Pharma Sciences Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Cohance Lifesciences Ltd and Solara Active Pharma Sciences Ltd?

As of May 5, 2026, the Cohance Lifesciences Ltd stock price is INR ₹469.95. On the other hand, Solara Active Pharma Sciences Ltd stock price is INR ₹518.4.

How do dividend payouts of Cohance Lifesciences Ltd and Solara Active Pharma Sciences Ltd compare?

To compare the dividend payouts of Cohance Lifesciences Ltd and Solara Active Pharma Sciences Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.